Effective for dates of service on or after April 1, the Healthcare Common Procedure Coding System (HCPCS) code J0491 is valid for billing 1 mg anifrolumab-fnia.
Search results for: anifrolumab
Anifrolumab Promising for Sustained Low Disease Activity in Patients with Lupus
ACR CONVERGENCE 2021—Using pooled data from the TULIP-1 and TULIP-2 clinical trials, researchers set out to identify whether more patients with systemic lupus erythematosus (SLE) being treated with anifrolumab achieved a low disease activity state than patients with SLE who received placebo.1-3 An analysis of the data was presented at ACR Convergence 2021 by Eric…
Anifrolumab Promising for SLE
Recent research has found a higher does of anifrolumab may benefit patients with moderate to severe SLE…
Highlights from the European Congress of Internal Medicine
An overview of highlights from the 2025 ECIM meeting, including research on treatment options for systemic sclerosis, the management of PMR & autoimmune testing.
Lupus Arthritis: Experts Describe Strides Made in Understudied Condition
ACR Convergence 2024—Arthritis symptoms related to lupus are a bit of a trouble spot for clinicians, with limited data to guide treatment and overlap with other conditions, experts said in a session at ACR Convergence. Lupus arthritis (LA), present in 95% of patients with lupus, is the main cause of work-related disability and is a…
Skin Matters: The Intersection of Dermatology & Rheumatology
Jun Kang, MD, addressed the intersection of dermatology and rheumatology, describing the nuance necessary to accurately evaluate skin manifestations and differentiate multiple conditions.
Toward Personalized Medicine in Pediatric Lupus
At this ACR Convergence 2024 session, discussion centered on novel techniques that offer hope for developing personalized therapies for pediatric SLE.
Exploring the Role of Neutrophil Extracellular Traps in Systemic Lupus Erythematosus
An understanding of the mechanisms underlying NET-mediated inflammation will empower clinicians to target therapies that can mitigate disease activity & improve outcomes in patients with lupus.
Anti-Nuclear Antibodies & Nuclear Molecules in Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease that primarily affects young women and causes a wide range of inflammatory manifestations. Its hallmark is the production of antibodies to components of the cell nucleus (anti-nuclear antibodies [ANAs]). …
Interferons in Systemic Lupus Erythematosus
Current knowledge of receptor-ligand interactions, cell signaling, and transcriptional regulation derive from studies of type I interferon. The design of novel therapeutics is informed by the advances in investigation of type I interferon, with the potential for important impacts on patient management.
- 1
- 2
- 3
- 4
- Next Page »